MENU
+Compare
XBI
ETF ticker: NYSE ARCA
AS OF
May 30, 04:06 PM (EDT)
Price
$79.39
Change
-$1.07 (-1.33%)
Net Assets
4.57B

XBI stock forecast, quote, news & analysis

The investment seeks to provide investment results that, before fees and expenses, correspond generally to the total return performance of the S&P Biotechnology Select Industry Index derived from the biotechnology segment of a U... Show more

Category: #Health
XBI
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
A.I.Advisor
published price charts
Interact to see
Advertisement
A.I.Advisor
a Summary for XBI with price predictions
May 29, 2025

Momentum Indicator for XBI turns positive, indicating new upward trend

XBI saw its Momentum Indicator move above the 0 level on May 28, 2025. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 94 similar instances where the indicator turned positive. In of the 94 cases, the stock moved higher in the following days. The odds of a move higher are at .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Moving Average Convergence Divergence (MACD) for XBI just turned positive on May 19, 2025. Looking at past instances where XBI's MACD turned positive, the stock continued to rise in of 54 cases over the following month. The odds of a continued upward trend are .

XBI moved above its 50-day moving average on May 29, 2025 date and that indicates a change from a downward trend to an upward trend.

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where XBI advanced for three days, in of 303 cases, the price rose further within the following month. The odds of a continued upward trend are .

The Aroon Indicator entered an Uptrend today. In of 215 cases where XBI Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Bearish Trend Analysis

The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In of 66 cases where XBI's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where XBI declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

XBI broke above its upper Bollinger Band on April 24, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are ABBVIE (NYSE:ABBV), Amgen (NASDAQ:AMGN), Gilead Sciences (NASDAQ:GILD), Regeneron Pharmaceuticals (NASDAQ:REGN), Biogen (NASDAQ:BIIB), Exact Sciences Corp (NASDAQ:EXAS), Incyte Corp (NASDAQ:INCY), Exelixis (NASDAQ:EXEL), Moderna (NASDAQ:MRNA), Sarepta Therapeutics (NASDAQ:SRPT).

Industry description

The investment seeks to provide investment results that, before fees and expenses, correspond generally to the total return performance of the S&P Biotechnology Select Industry Index derived from the biotechnology segment of a U.S. total market composite index. In seeking to track the performance of the S&P Biotechnology Select Industry Index (the "index"), the fund employs a sampling strategy. It generally invests substantially all, but at least 80%, of its total assets in the securities comprising the index. The index represents the biotechnology segment of the S&P Total Market Index ("S&P TMI").

Market Cap

The average market capitalization across the SPDR® S&P Biotech ETF ETF is 7.87B. The market cap for tickers in the group ranges from 120.07M to 322.43B. ABBV holds the highest valuation in this group at 322.43B. The lowest valued company is EBS at 120.07M.

High and low price notable news

The average weekly price growth across all stocks in the SPDR® S&P Biotech ETF ETF was 31%. For the same ETF, the average monthly price growth was 85%, and the average quarterly price growth was 142%. ORIC experienced the highest price growth at 34%, while RCKT experienced the biggest fall at -60%.

Volume

The average weekly volume growth across all stocks in the SPDR® S&P Biotech ETF ETF was 116%. For the same stocks of the ETF, the average monthly volume growth was 39% and the average quarterly volume growth was 139%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 60
P/E Growth Rating: 78
Price Growth Rating: 67
SMR Rating: 82
Profit Risk Rating: 85
Seasonality Score: 16 (-100 ... +100)
View a ticker or compare two or three
XBI
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I. Advisor
published General Information

General Information

Category Health

Profile
Fundamentals
Details
Category
Health
Address
SPDR Series TrustOne Lincoln Street Cph0326Boston
Phone
N/A
Web
www.spdrs.com